Philips CPAP Recall and Chronic Lung Disease
Based on available evidence, there is one documented case report of interstitial lung disease associated with degraded foam from recalled Philips CPAP devices, which resolved after discontinuation of the device 1. However, this represents extremely limited evidence—a single case report—and does not establish a widespread pattern of chronic lung disease development from these machines.
What We Know About the Recall
The Philips Respironics recall in June 2021 involved polyurethane foam degradation in positive airway pressure devices. The foam breakdown released particles and chemical byproducts that could be inhaled, creating legitimate concerns about respiratory effects 1, 2.
Evidence of Chronic Lung Disease
Single Case Report
A 2025 case report documented one patient with obstructive sleep apnea and pre-existing COPD who developed interstitial lung disease temporally associated with using a recalled device 1. Key features:
- Patient noted sediment in the CPAP tubing system
- Developed new interstitial lung disease
- Condition resolved after stopping the recalled device
- This suggests the foam degradation products had an irritative effect on airways
Important Context
The case report specifically notes that studies have not shown an increased incidence of neoplastic (cancer) processes among users of recalled devices 1. However, research examining other respiratory conditions remains limited.
Impact of the Recall
The recall affected over 700,000 Veterans in the VHA system alone 3, and created significant clinical dilemmas:
- 62.4% of clinicians recommended patients continue using recalled devices (balancing unknown risks against known risks of untreated sleep apnea) 2
- Only 9.3% of clinicians encouraged stopping device use 2
- 59.9% of patients continued treatment with recalled devices while awaiting replacements 2
- Replacement wait times exceeded one year for many patients 3
Clinical and Psychological Impact
- 91.5% of clinicians reported the recall affected their patients' health and well-being 2
- 83.3% reported it affected patients' trust in medicine 2
- 86.8% of clinicians experienced increased stress levels 2
Clinical Implications
The risk-benefit calculation heavily favored continued CPAP use for most patients, as untreated obstructive sleep apnea carries well-established risks including:
- Cardiovascular morbidity and mortality
- Neurocognitive impairment
- Daytime dysfunction and accident risk
The VHA response prioritized a clinician-led approach with device allocation based on clinical need rather than purely administrative criteria 3. This framework appropriately recognized that stopping CPAP therapy posed greater immediate health risks for most patients than the uncertain risks from foam degradation.
Bottom Line
While one case of reversible interstitial lung disease has been documented, there is no evidence of widespread chronic lung disease development from recalled Philips CPAP machines. The single case report suggests foam degradation can cause airway irritation and inflammation that resolves with device discontinuation, but this does not constitute an epidemic of chronic lung disease among the millions of affected users.
For patients still using recalled devices: prioritize obtaining replacement devices through your healthcare provider, but the decision to continue use should be individualized based on severity of sleep apnea, availability of alternatives, and presence of new respiratory symptoms.